

## List of Figures

<b>Figure No.</b>	<b>Description</b>	<b>Page No.</b>
2.1	(I) Diagrammatic illustration of the gastrointestinal-transit of nanocarriers and subsequent their intestinal permeation. (II) Graphics illustrating the various routes of absorption of nanocarriers across GIT.	18
4.1	UV-Visible absorbance spectra of pure CS in water	65
4.2	UV-Visible absorbance spectra of pure CS in phosphate buffer pH 7.4	65
4.3	Calibration curve of CS by UV-Visible spectroscopy in water	66
4.4	Calibration curve of CS by UV-Visible spectroscopy in phosphate buffer pH 7.4	66
4.5	Typical chromatograms of (A) blank plasma, (B) pure CS and (C) plasma spiked with CS	70
4.6	Calibration curve of CS by RP-HPLC in rat plasma	71
5.1	Solubility profile of CS in different media at $25 \pm 2$ °C	94
5.2	FTIR spectra of (a) CS, (b) PLGA, (c) PVA and (d) physical mixture	95
5.3	DSC thermograms of (a) CS, (b) PLGA, (c) PVA and (d) physical mixture	97
5.4	Pareto charts showing the significant effect of independent variables on (A) particle size, (B) EE and (C) PDI of CS-PNs during Plackett-Burman screening design	101
5.5	3D response surface plots (A), (C) and 2D contour plots (B), (D) showing the effect of independent variables (concentration of polymer, concentration of surfactant and organic phase/aqueous phase ratio) on particle size of CS-PNs	109
5.6	3D response surface plots (A), (C) and 2D contour plots (B), (D) showing the effect of independent variables (concentration of polymer, concentration of surfactant and organic phase/aqueous phase ratio) on encapsulation efficiency of CS-PNs	112

5.7	3D response surface plots (A), (C) and 2D contour plots (B), (D) showing the effect of independent variables (concentration of polymer, concentration of surfactant and organic phase/aqueous phase ratio) on PDI of CS-PNs	114
5.8	FTIR spectra of (a) CS, (b) PLGA, (c) PVA and (d) optimized CS-PNs	117
5.9	DSC thermograms of (a) CS, (b) PLGA, (c) PVA and (d) optimized CS-PNs	118
5.10	PXRD patterns of (a) PLGA, (b) CS, (c) PVA, (d) physical mixture and (e) optimized CS-PNs	120
5.11	(A) HR-TEM image of optimized CS-PNs; (B) Electron diffraction pattern of optimized CS-PNs	121
5.12	AFM images of optimized CS-PNs (A) 2D micrograph and (B) corresponding 3D micrographs	122
5.13	<i>In-vitro</i> drug release profile of optimized CS-PNs in phosphate buffer pH 7.4	124
5.14	Effect on (A) particle size, (B) encapsulation efficiency and (c) PDI of optimized CS-PNs stored at different environmental conditions over different time interval	127
5.15	<i>Ex-vivo</i> permeation study of CS-PNs and CS solution across rat intestinal membrane	129
5.16	Apparent permeability coefficients (Papp) for CS from CS-PNs and CS solution	130
5.17	Confocal laser scanning micrographs of rat intestine, showing uptake and transport of FITC tagged CS-PNs into the tissues, underlying the absorptive cells, after 2 hr of oral administration	131
5.18	Plasma drug concentration time profile of CS-PNs and CS solution following single dose oral administration in rats; Dose: 20 mg/kg	133
5.19	Effect of oral administration of CS solution and CS-PNs on degranulation of peritoneal mast cells in rats (Dose: 20 mg/kg)	136
6.1	FTIR spectra of (a) CS, (b) GMS, (c) PVA and (d) physical mixture	148
6.2	DSC thermograms of (a) CS, (b) GMS, (c) PVA and (d) physical mixture	149

6.3	Pareto charts showing the significant effect of independent variables on (A) particle size, (B) EE and (C) PDI of CS-SLNs during Plackett-Burman screening design.	158
6.4	3D surface plots (A), (C) and 2D contour plots (B), (D) showing the effect of independent variables (concentration of lipid, concentration of surfactant and organic phase/aqueous phase ratio) on particle size of CS-SLNs	167
6.5	3D response surface plots (A), (C) and 2D contour plots (B), (D) showing the effect of independent variables (concentration of lipid, concentration of surfactant and organic phase/aqueous phase ratio) on encapsulation efficiency of CS-SLNs	169
6.6	3D response surface plots (A), (C) and 2D contour plots (B), (D) showing the effect of independent variables (concentration of lipid, concentration of surfactant and organic phase/aqueous phase ratio) on PDI of CS-SLNs	172
6.7	FTIR spectra of (a) CS, (b) GMS, (c) PVA and (d) optimized CS-SLNs	175
6.8	DSC thermograms of (a) CS, (b) GMS, (c) PVA and (d) optimized CS-SLNs	176
6.9	PXRD patterns of (a) GMS, (b) CS, (c) PVA, (d) physical mixture and (e) optimized CS-SLNs	178
6.10	(A) HR-TEM image of optimized CS-SLNs; (B) Electron diffraction pattern of optimized CS-SLNs	179
6.11	AFM images of optimized CS-SLNs (A) 2D micrograph and (B) corresponding 3D micrographs	180
6.12	<i>In-vitro</i> drug release profile of optimized CS-SLNs in phosphate buffer pH 7.4	182
6.13	Effect on (A) particle size, (B) encapsulation efficiency and (c) PDI of optimized CS-SLNs stored at different environmental conditions over different time interval	185
6.14	<i>Ex-vivo</i> permeation study of CS-SLNs and CS solution across rat intestinal membrane	187

6.15	Apparent permeability coefficients (Papp) for CS from CS-SLNs and CS solution	188
6.16	Confocal laser scanning micrographs of rat intestine, showing uptake and transport of coumarin-6 labelled CS-SLNs into the tissues, underlying the absorptive cells, after 2 hr of oral administration	189
6.17	Plasma drug concentration time profile of CS-SLNs and CS solution following single dose oral administration in rats; Dose: 20 mg/kg	191
6.18	Effect of oral administration of CS solution and CS-SLNs on degranulation of peritoneal mast cells in rats (Dose: 20 mg/kg)	193
7.1	FTIR spectra of (a) CS, (b) PLGA, (c) soya lecithin, (d) PVA and (e) physical mixture	208
7.2	DSC thermograms of (a) CS, (b) PLGA, (c) soya lecithin, (d) PVA and (e) physical mixture	209
7.3	Pareto charts showing the significant effect of independent variables on (A) particle size, (B) EE and (C) PDI of CS-PLHNs during Plackett-Burman screening design	214
7.4	3D response surface plots (A), (C) and 2D contour plots (B), (D) showing the effect of independent variables (lipid/polymer ratio, concentration of surfactant, organic phase/aqueous phase ratio and concentration of polymer) on particle size of CS-PLHNs	223
7.5	3D response surface plots (A), (C) and 2D contour plots (B), (D) showing the effect of independent variables (lipid/polymer ratio, concentration of surfactant, organic phase/aqueous phase ratio and concentration of polymer) on encapsulation efficiency of CS-PLHNs	226
7.6	3D response surface plots (A), (C) and 2D contour plots (B), (D) showing the effect of independent variables (lipid/polymer ratio, concentration of surfactant, organic phase/aqueous phase ratio and concentration of polymer) on PDI of CS-PLHNs	229
7.7	FTIR spectra of (a) CS, (b) PLGA, (c) soya lecithin, (d) PVA and (e) optimized CS-PLHNs	233

7.8	DSC thermograms of (a) CS, (b) PLGA, (c) soya lecithin, (d) PVA and (e) optimized CS-PLHNs	234
7.9	PXRD patterns of (a) CS, (b) PLGA, (c) soya lecithin, (d) PVA, (e) physical mixture and (f) optimized CS-PLHNs	236
7.10	(A) HR-TEM image of optimized CS-PLHNs, Inset image shows core-shell architecture of the CS-PLHNs; (B) Electron diffraction pattern of optimized CS-PLHNs	238
7.11	AFM images of optimized CS-PLHNs (A) 2D micrograph and (B) corresponding 3D micrographs	239
7.12	(A) Fluorescent confocal microscopic image and (B) 3D - Confocal microscopic image of micron sized CS-PLHNs tagged with FITC, showing core-shell architecture	240
7.13	<i>In-vitro</i> drug release profile of optimized CS-PLHNs in phosphate buffer pH 7.4	242
7.14	Effect on (A) particle size, (B) encapsulation efficiency and (c) PDI of optimized CS-PLHNs stored at different environmental conditions over different time interval	245
7.15	<i>Ex-vivo</i> permeation study of CS-PLHNs and CS solution across rat intestinal membrane	247
7.16	Apparent permeability coefficients (Papp) for CS from CS-PLHNs and CS solution	248
7.17	Confocal laser scanning micrographs of rat intestine, showing uptake and transport of FITC tagged CS-PLHNs into the tissues, underlying the absorptive cells, after 2 hr of oral administration	249
7.18	Plasma drug concentration time profile of CS-PLHNs and CS solution following single dose oral administration in rats; Dose: 20 mg/kg	251
7.19	Effect of oral administration of CS solution and CS-PLHNs on degranulation of peritoneal mast cells in rats (Dose: 20 mg/kg)	254
8.1	FTIR spectra of (a) CS, (b) PCL, (c) chitosan, (d) poloxamer 188 and (e) physical mixture	269
8.2	DSC thermograms of (a) CS, (b) PCL, (c) chitosan, (d) poloxamer 188 and (e) physical mixture	271

8.3	Pareto charts showing the significant effect of independent variables on (A) particle size, (B) EE and (C) PDI of CS-PCCSNs during Plackett-Burman screening design	275
8.4	3D response surface plots (A), (C) and 2D contour plots (B), (D) showing the effect of independent variables (concentration of PCL, concentration of chitosan and concentration of surfactant) on particle size of CS-PCCSNs	284
8.5	3D response surface plots (A), (C) and 2D contour plots (B), (D) showing the effect of independent variables (concentration of PCL, concentration of chitosan and concentration of surfactant) on encapsulation efficiency of CS-PCCSNs	287
8.6	3D response surface plots (A), (C) and 2D contour plots (B), (D) showing the effect of independent variables (concentration of PCL, concentration of chitosan and concentration of surfactant) on PDI of CS-PCCSNs	290
8.7	FTIR spectra of (a) CS, (b) PCL, (c) chitosan, (d) poloxamer 188 and (e) optimized CS-PCCSNs	293
8.8	DSC thermograms of (a) CS, (b) PCL, (c) chitosan, (d) poloxamer 188 and (e) optimized CS-PCCSNs	295
8.9	PXRD patterns of (a) CS, (b) PCL, (c) chitosan, (d) poloxamer 188, (e) physical mixture and (f) optimized CS-PCCSNs	296
8.10	HR-TEM image of optimized CS-PCCSNs, Inset image shows core-shell architecture of the CS-PCCSNs; (B) Electron diffraction pattern of optimized CS-PCCSNs	298
8.11	AFM images of optimized CS-PCCSNs (A) 2D micrograph and (B) corresponding 3D micrographs	300
8.12	(A) Fluorescent confocal microscopic image and (B) 3D - Confocal microscopic image of micron sized CS-PCCSNs tagged with FITC, showing core-shell architecture	301
8.13	<i>In-vitro</i> drug release profile of optimized CS-PCCSNs in phosphate buffer pH 7.4	303

8.14	Effect on (A) particle size, (B) encapsulation efficiency and (c) PDI of optimized CS-PCCSNs stored at different environmental conditions over different time interval	305
8.15	<i>Ex-vivo</i> permeation study of CS-PCCSNs and CS solution across rat intestinal membrane	307
8.16	Apparent permeability coefficients (Papp) for CS from CS-PCCSNs and CS solution	308
8.17	Confocal laser scanning micrographs of rat intestine, showing uptake and transport of FITC tagged CS-PCCSNs into the tissues, underlying the absorptive cells, after 2 hr of oral administration	310
8.18	Plasma drug concentration time profile of CS-PCCSNs and CS solution following single dose oral administration in rats; Dose: 20 mg/kg	312
8.19	Effect of oral administration of CS solution and CS-PCCSNs on degranulation of peritoneal mast cells in rats (Dose: 20 mg/kg)	315
9.1	Comparative <i>in-vitro</i> drug release profiles of different optimized nanocarriers in phosphate buffer pH 7.4	322
9.2	Comparative <i>ex-vivo</i> permeation studies of CS solution and different optimized CS encapsulated nanocarriers across rat intestinal membrane	324
9.3	Comparative plasma drug concentration time profiles of CS solution and different optimized CS encapsulated nanocarriers following single dose oral administration in rats; Dose: 20 mg/kg	327